Android app on Google Play

UPDATE: Jefferies Starts Pluristem Therapeutics (PSTI) at Hold

March 18, 2013 5:40 PM EDT Send to a Friend
Get Alerts PSTI Hot Sheet
Price: $2.87 -2.38%

Rating Summary:
    7 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 25 | New: 14
Trade PSTI Now!
Join SI Premium – FREE
(Updated - March 19, 2013 7:10 AM EDT)

Jefferies initiates coverage on Pluristem Therapeutics (NASDAQ: PSTI) with a Hold. PT $3.50.

The firm comments, "Positives for PSTI include (1) real unmet need/large market potential in peripheral arterial disease (PAD) and (2) proprietary stem-cell technology platform & its potential for broad applicability. Challenges are (1) yet-to-be proven clinical efficacy of PLX cells; (2) Ph2 PLX-PAD data not until ~late-2014/early-2015; (3) difficult-to-treat PAD lead indication; and (4) potential clinical/regulatory hurdles for stem-cell products."

For an analyst ratings summary and ratings history on Pluristem Therapeutics click here. For more ratings news on Pluristem Therapeutics click here.

Shares of Pluristem Therapeutics closed at $3.08 yesterday.




You May Also Be Interested In


Related Categories

New Coverage

Related Entities

Jefferies & Co

Add Your Comment